The United Kingdom and the United States have signed a landmark trade agreement that will preserve zero import taxes on UK medicine exports entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This pledge secures that tariffs on these vital goods will be held at zero for a timeframe of three years.
This development follows previous threats to hike tariffs on patented drug imports, with figures floated reaching double the cost.
"This deal between the UK strengthens the global environment for new treatments and introduces long-overdue balance to transatlantic pharmaceutical trade," an announcement said.
Trade Impact
Pharmaceuticals constitute one of the Britain's most significant exports to the America, which is clearly the biggest market for leading companies like GSK and AstraZeneca.
Export figures show that in the one-year period to the end of September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This figure made up 17.4% of British export trade in that span.
"This guarantee secures employment, stimulates investment and facilitates the UK to establish itself as a international leader for life sciences," a government official stated.
Specific NHS Changes
The pact includes several notable changes from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates were more than twenty percent.
Broader Context
The pact comes amid a long-running row between the sector and the British authorities over medicine costs and NHS adoption.
The disagreement were heightened by claims that US patients were paying several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS must spend more on drugs, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the past decade.
